Abstract
In eukaryotes, genes consist in coding sequences (exons) interspersed with non-coding ones (introns). The regulation of alternative inclusion/exclusion of exons, or part of exons, during the maturation of the pre-mRNA into mRNA (alternative splicing) allows a dramatic increase of the protein versus the gene repertoire. In a number of cases, alternative splicing decision generates proteins with distinct, sometimes opposite, functions from a given gene. Angiogenesis is the process of vascularisation in physiological conditions and a series of pathologies, including cancer where it favours tumour progression and dissemination of metastasis. In this issue, we discuss some key examples showing how alternative splicing may induce a switch from anti-angiogenic to pro-angiogenic functions reciprocally. For some of these splicing events, the molecular mechanisms that trigger alternative splicing toward one or the other direction start to be elucidated. The emergence of strategies enabling to regulate alternative splicing opens new routes for anti-angiogenic therapies.
Keywords: Alternative splicing, angiogenesis, small molecules angiogenesis inhibitors, VEGF, VEGF111, constitutive splicing, isoforms, SRPK, ischemia, hypertension, preeclampsia, Denys-Drash syndrome, ELISA, Neuropilins, RTKs, metalloproteinase-17, semaphorins, plexin-1, Sema3A, Tie-2, Ang-2, VASH1, SULF-1, CAM assay, SDF-1, CXCR4, CXCR7, Neuregulin-2, Fibronectin, Migration-stimulating factor, MSF, CD44, PECAM-1/CD31, MAPK/ERK, HYAL-1, Hyaluronidase-1, TrpRS, Signalling Molecules, KLF6, camptothecin, doxorubicin, cis-platinum, Epigallocatechin gallate, Duch-ene muscular dystrophy, HDAC, Topoisomerase I, Topoisomerase II, CLK kinases, GSK3, Protein phosphatase 1, cAMP pathway, Transcription-splicing coupling, cystic fibrosis
Current Pharmaceutical Design
Title: Alternative Splicing: A Promising Target for Pharmaceutical Inhibition of Pathological Angiogenesis?
Volume: 16 Issue: 35
Author(s): Carine Munaut, Alain C. Colige and Charles A. Lambert
Affiliation:
Keywords: Alternative splicing, angiogenesis, small molecules angiogenesis inhibitors, VEGF, VEGF111, constitutive splicing, isoforms, SRPK, ischemia, hypertension, preeclampsia, Denys-Drash syndrome, ELISA, Neuropilins, RTKs, metalloproteinase-17, semaphorins, plexin-1, Sema3A, Tie-2, Ang-2, VASH1, SULF-1, CAM assay, SDF-1, CXCR4, CXCR7, Neuregulin-2, Fibronectin, Migration-stimulating factor, MSF, CD44, PECAM-1/CD31, MAPK/ERK, HYAL-1, Hyaluronidase-1, TrpRS, Signalling Molecules, KLF6, camptothecin, doxorubicin, cis-platinum, Epigallocatechin gallate, Duch-ene muscular dystrophy, HDAC, Topoisomerase I, Topoisomerase II, CLK kinases, GSK3, Protein phosphatase 1, cAMP pathway, Transcription-splicing coupling, cystic fibrosis
Abstract: In eukaryotes, genes consist in coding sequences (exons) interspersed with non-coding ones (introns). The regulation of alternative inclusion/exclusion of exons, or part of exons, during the maturation of the pre-mRNA into mRNA (alternative splicing) allows a dramatic increase of the protein versus the gene repertoire. In a number of cases, alternative splicing decision generates proteins with distinct, sometimes opposite, functions from a given gene. Angiogenesis is the process of vascularisation in physiological conditions and a series of pathologies, including cancer where it favours tumour progression and dissemination of metastasis. In this issue, we discuss some key examples showing how alternative splicing may induce a switch from anti-angiogenic to pro-angiogenic functions reciprocally. For some of these splicing events, the molecular mechanisms that trigger alternative splicing toward one or the other direction start to be elucidated. The emergence of strategies enabling to regulate alternative splicing opens new routes for anti-angiogenic therapies.
Export Options
About this article
Cite this article as:
Munaut Carine, C. Colige Alain and A. Lambert Charles, Alternative Splicing: A Promising Target for Pharmaceutical Inhibition of Pathological Angiogenesis?, Current Pharmaceutical Design 2010; 16 (35) . https://dx.doi.org/10.2174/138161210794455012
DOI https://dx.doi.org/10.2174/138161210794455012 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacogenetics Strategies: From Candidate Genes to Whole-Genome Association Analysis. Exploratory or Confirmatory Studies?
Current Pharmacogenomics and Personalized Medicine CXCR4 and Glioblastoma
Anti-Cancer Agents in Medicinal Chemistry Self-immolative Linkers in Prodrugs and Antibody Drug Conjugates in Cancer Treatment
Recent Patents on Anti-Cancer Drug Discovery The Cancer Preventive Effects of Edible Mushrooms
Anti-Cancer Agents in Medicinal Chemistry The Importance of Rhodanine Scaffold in Medicinal Chemistry: A Comprehensive Overview
Mini-Reviews in Medicinal Chemistry Fusogenic Oncolytic Herpes Simplex Viruses as a Potent and Personalized Cancer Vaccine
Current Pharmaceutical Biotechnology Applications of Gene Therapy to the Treatment of Chronic Pain
Current Gene Therapy Nanoliposome is a Promising Carrier of Protein and Peptide Biomolecule for the Treatment of Cancer
Anti-Cancer Agents in Medicinal Chemistry Tumour Hypoxia and Technetium Tracers: In Vivo Studies
Current Radiopharmaceuticals Combination of Photodynamic Therapy with Anti-Cancer Agents
Current Medicinal Chemistry Thirty Years of Polyamine-Related Approaches to Cancer Therapy. Retrospect and Prospect. Part 1. Selective Enzyme Inhibitors
Current Drug Targets An Enzyme-responsive Porphyrin Metal-organic Framework Nanosystem for Targeted and Enhanced Synergistic Cancer Photo-chemo Therapy
Current Drug Delivery Adenovirus-based Immunotherapy for Prostate Cancer
Current Cancer Therapy Reviews Recent Patents on Thiazole Derivatives Endowed with Antitumor Activity
Recent Patents on Anti-Cancer Drug Discovery Hypericin Lights Up the Way for the Potential Treatment of Nasopharyngeal Cancer by Photodynamic Therapy
Current Clinical Pharmacology MCDCalc: Markov Chain Molecular Descriptors Calculator for Medicinal Chemistry
Current Topics in Medicinal Chemistry Folate Based Radiopharmaceuticals for Imaging and Therapy of Cancer and Inflammation
Current Pharmaceutical Design Short-Term Intra-Nasal Erythropoietin Administration with Low Sialic Acid Content is without Toxicity or Erythropoietic Effects
Current Neurovascular Research Follow the ATP: Tumor Energy Production: A Perspective
Anti-Cancer Agents in Medicinal Chemistry Radiolabeled Nanoparticles for Cancer Diagnosis and Therapy
Anti-Cancer Agents in Medicinal Chemistry